{
    "clinical_study": {
        "@rank": "75482", 
        "arm_group": {
            "arm_group_label": "Intent-to-treat population with aCRC or mCRC", 
            "description": "Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      The primary objective is to validate previously identified predictive/prognostic genomic DNA\n      and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced\n      CRC (a CRC) or metastatic CRC (mCRC).\n\n      Secondary Objective:\n\n        1. To test the efficacy of bvz in combination with FOLFOX in patients with newly diagnosed\n           advanced or metastatic K-ras mutant CRC and\n\n        2. To determine the progression free and overall survival of patients under first line\n           FOLFOX + bvz in aCRC or mCRC."
        }, 
        "brief_title": "ANGIOPREDICT. ICORG 12-16, V3", 
        "condition": "Advanced Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Study Design:\n\n      Type of Study: Exploratory, translational, multicenter and multinational Phase II study.\n\n      Patient Population:All patients from the intent-to-treat population with aCRC or mCRC,\n      (incurable with any conventional multimodality approach) and who fulfil all inclusion and\n      exclusion criteria.\n\n      Number of Patients: 224\n\n      Sample Type:\n\n      Serial tissue and blood samples will be collected before (week 0), during (week 6, month 3\n      and 6) and at the end of treatment (month 12)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients \u2265 18 years of age.\n\n          2. Patients diagnosed with recurrent or de novo, locally advanced (unresectable) or\n             metastatic adenocarcinoma of the colon or rectum.\n\n          3. Planned combination bevacizumab (bvz) treatment with either:\n\n               -  leucovorin, fluorouracil and oxaliplatin (FOLFOX)\n\n               -  capecitabine and oxaliplatin (XELOX)\n\n               -  leucovorin, fluorouracil and irinotecan (FOLFIRI)\n\n               -  capecitabine and irinotecan (XELIRI)\n\n          4. Naive for bvz\n\n          5. An evaluable site of disease\n\n          6. ECOG Performance status 0, 1, or 2\n\n          7. Adequate renal function as shown by serum creatinine \u2264 1.5 x ULN or GFR \u2265 50ml/min\n\n          8. Adequate hematopoietic function [white blood cell (WBC) count \u2265 3000/\u03bcl, absolute\n             neutrophil count (ANC) \u22651500/\u03bcl, platelets \u2265100 000/\u03bcl, haemoglobin level \u2265 9.0 g/dl]\n\n          9. Adequate end organ function, defined as the following: total bilirubin < 1.5 x ULN,\n             SGOT and SGPT < 3.0 x ULN (in case of liver metastases SGOT and SGPT < 5.0 x ULN)\n\n         10. Ability to give signed informed consent prior to any screening procedures\n\n         11. FFPE Tissue is available\n\n        Exclusion Criteria:\n\n          1. Patient has received any other investigational product within 28 days of first day of\n             study drug dosing\n\n          2. Patients having familial and/or hereditary CRC\n\n          3. CRC associated with ulcerative colitis\n\n          4. Patient with any significant history of non-compliance to medical regimens or with\n             inability to grant reliable informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients from the intent-to-treat population with aCRC or mCRC, (incurable with any\n        conventional multimodality approach) and who fulfil all inclusion and exclusion criteria."
            }
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822444", 
            "org_study_id": "ICORG 12-16"
        }, 
        "intervention": {
            "arm_group_label": "Intent-to-treat population with aCRC or mCRC", 
            "intervention_name": "Biomarker analysis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Colorectal Cancer", 
            "Advanced Colorectal Cancer", 
            "Metastatic Colorectal Cancer", 
            "Locally Advanced Colorectal Cancer", 
            "Colon Cancer", 
            "Rectal Cancer"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01 2214000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland", 
                        "zip": "D4"
                    }, 
                    "name": "St Vincent's University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ray McDermott, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "01 4142000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "The Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Ray McDermott, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact Person", 
                    "phone": "01 4103000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St James Hospital"
                }, 
                "investigator": {
                    "last_name": "John Kennedy, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Martin, Dr", 
                    "phone": "071-9171111"
                }, 
                "facility": {
                    "address": {
                        "city": "Sligo", 
                        "country": "Ireland"
                    }, 
                    "name": "Sligo General Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael martin, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Identification of biomarkers, which are predictive for response and/or prolonged PFS to FOLFOX/bvz combination therapy in aCRC or mCRC patients.", 
            "measure": "Identification of biomarkers", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Validation of identified biomarkers with regard to response rate/failure to further treatment strategy, PFS, overall survival (OS) and toxicity.", 
            "measure": "Validation of identified biomarkers", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}